Drug Profile
Research programme: cancer therapeutics - Actavia Life Sciences
Alternative Names: NPM1 programmeLatest Information Update: 25 Jan 2024
Price :
$50
*
At a glance
- Originator Rasna Therapeutics
- Developer Actavia Life Sciences
- Class Antineoplastics
- Mechanism of Action Enzyme inhibitors; Nucleophosmin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Haematological malignancies
Most Recent Events
- 20 Sep 2023 Research programme is still in preclinical development in Haematological-malignancies in United Kingdom (Rasna therapeutics pipeline, September 2023)
- 28 Sep 2020 No recent reports of development identified for preclinical development in Haematological-malignancies in United Kingdom
- 17 Aug 2016 Preclinical trials in Haematological malignancies in United Kingdom (unspecified route)